Phillip W. Berman

TL;DR: V vaccines that are designed to induce higher levels of V1V2 antibodies and lower levels of Env-specific IgA antibodies than are induced by the RV144 vaccine may have improved efficacy against HIV-1 infection.

TL;DR: Using in vitro mutagenesis, it is found that deletion of 12 amino acids from this region of gp120 leads to a complete loss of binding and a single amino acid substitution in this region results in significantly decreased binding, suggesting that sequences within this region are directly involved in the binding of gp 120 to the CD4 receptor.

TL;DR: It is demonstrated that recombinant gp120, formulated in an adjuvant approved for human use, can elicit protective immunity against a homologous strain of HIV-1.

TL;DR: HIV-1–specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine, and should be evaluated in future HIV-1 vaccine efficacy trials to further refine immune correlates of protection.

TL;DR: Antibodies directed against the recombinant molecule were found to react with the envelope glycoprotein produced in virus-infected cells, which should provide sufficient quantities of the AIDS retrovirus envelope protein for biological and vaccination studies.